| Database ID | Agent | Target | Cancer Type | Detail |
| DB00346 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00347 | cetuximab | EGFR | head and neck cancer | view |
| DB00348 | cetuximab | EGFR | head and neck cancer | view |
| DB00349 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00350 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00351 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00352 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00353 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00354 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00355 | cetuximab | Epidermal growth factor receptor | head and neck cancer | view |
| DB00356 | C225 | Epidermal growth factor receptor | head and neck cancer | view |
| DB00357 | ridaforolimus | Serine/threonineprotein kinase mTOR | advanced solid tumors | view |
| DB00358 | lenvatinib | Alpha plateletderived growth factor receptor
Mast/stem cell growth factor receptor
Protooncogene tyrosineprotein kinase receptor ret
VEGF receptor
Fibroblast growth factor receptor | thyroid cancer | view |
| DB00359 | afatinib | Receptor proteintyrosine kinase erbB2
Epidermal growth factor receptor | head and neck cancer | view |
| DB00360 | afatinib | Receptor proteintyrosine kinase erbB2
Epidermal growth factor receptor | head and neck cancer | view |